Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa-Reference-Cited by-同舟云学术

Efficacy and safety of three second-line antiretroviral regimens in HIV-infected patients in Africa

Published:2015-07-31 Issue:12 Volume:29 Page:1473-1481
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Ciaffi Laura,Koulla-Shiro Sinata,Sawadogo Adrien,le Moing Vincent,Eymard-Duvernay Sabrina,Izard Susanne,Kouanfack Charles,Ngom Gueye Ndeye Fatou,Fobang Avelin Aghokeng,Reynes Jacques,Calmy Alexandra,Delaporte Eric

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Infectious Diseases,Immunology,Immunology and Allergy

Reference16 articles.

1. Persistent difficulties in switching to second-line ARTin sub-Saharan Africa: a systematic review and meta-analysis.;Madec;PLoS One,2013

2. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND LINE): a randomized, open label, noninferiority study.;Lancet,2013

3. Assessment of second-line antiretroviral regimens for HIV therapy in Africa.;Paton;N Engl J Med,2014

4. UK EPI team. Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B5701 in HIV-1-infected UK subjects.;Orkin;HIV Med,2010

5. The dynamic of adherence to highly active antiretroviral therapy: results from the French National APROCO cohort.;Carrieri;J Acquir Immune Defic Syndr,2001

Cited by 39 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial;The Lancet HIV;2022-06

2. Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa;Annals of Internal Medicine;2021-12

3. APOL1 Renal Risk Variants and Kidney Function in HIV-1–Infected People From Sub-Saharan Africa;Kidney International Reports;2021-10

4. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV;New England Journal of Medicine;2021-07-22

5. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial);PharmacoEconomics;2020-12-23